M&A Deal Summary

ArchiMed Acquires WiQo

On March 9, 2023, private equity firm ArchiMed acquired consumer products company WiQo

Acquisition Highlights
  • This is ArchiMed’s 3rd transaction in the Consumer Products sector.
  • This is ArchiMed’s 6th transaction in Italy.

M&A Deal Summary

Date 2023-03-09
Target WiQo
Sector Consumer Products
Buyer(s) ArchiMed
Deal Type Buyout (LBO, MBO, MBI)

Target

WiQo

Milan, Italy
website
WiQo focuses on the development, manufacturing, and distribution of non-invasive and non-surgical skin health medical devices with scientifically validated efficacy and safety. WiQo was founded in 1994 and is based in Milan, Italy.

Search 195,076 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ArchiMed

Investor Investor Investor Investor Investor

website


Category Private Equity Firm
Founded 2014
PE ASSETS 8.0B EUR
Size Mega
Type Sector Focused
DESCRIPTION

ArchiMed is a specialist French private equity firm focused on buyouts of and growth capital investments in European healthcare-oriented companies. The Firm looks to invest €10 million to €1 billion per transaction and specifically targets companies in the public health, care and wellness, biotech, and medical technology segments of the healthcare industry. ArchiMed was formed in 2014 and is headquartered in Lyon.


DEAL STATS #
Overall 33 of 36
Sector (Consumer Products) 3 of 4
Type (Buyout (LBO, MBO, MBI)) 18 of 20
Country (Italy) 6 of 6
Year (2023) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-12-07 Xpress Biologics

Milmort, Belgium

Xpress Biologics is a developer of expression systems and manufacturing processes for the production of plasmid DNA and protein therapeutics. Xpress Biologics was founded in 2014 and is based in Milmort, Belgium.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-03-31 Polyplus

Illkirch, France

Polyplus is a biotechnology company that supports Gene and Cell therapy, biologics manufacturing, and life science research with innovative nucleic acid transfection solutions. Polyplus was founded in 2001 and is based in Illkirch, France.

Sell €2.4B